Equities analysts expect LivaNova PLC (NASDAQ:LIVN) to post $0.52 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for LivaNova’s earnings, with estimates ranging from $0.49 to $0.55. LivaNova posted earnings per share of $0.71 during the same quarter last year, which suggests a negative year-over-year growth rate of 26.8%. The company is expected to announce its next quarterly earnings report on Wednesday, February 23rd.
On average, analysts expect that LivaNova will report full year earnings of $1.99 per share for the current financial year, with EPS estimates ranging from $1.85 to $2.07. For the next year, analysts forecast that the company will report earnings of $2.51 per share, with EPS estimates ranging from $2.25 to $2.64. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow LivaNova.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, November 3rd. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.23. LivaNova had a negative net margin of 39.33% and a positive return on equity of 10.04%. The business had revenue of $253.20 million during the quarter, compared to analyst estimates of $245.24 million. During the same period in the prior year, the firm earned $0.38 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Friday, October 1st. The stock was sold at an average price of $80.00, for a total value of $80,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Alfred J. Novak sold 644 shares of the stock in a transaction that occurred on Wednesday, November 10th. The stock was sold at an average price of $90.77, for a total value of $58,455.88. The disclosure for this sale can be found here. Insiders sold a total of 3,644 shares of company stock valued at $306,106 over the last quarter. Company insiders own 0.37% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sachem Head Capital Management LP purchased a new position in shares of LivaNova during the second quarter valued at approximately $74,858,000. Schroder Investment Management Group bought a new stake in shares of LivaNova during the first quarter valued at approximately $63,566,000. Millennium Management LLC raised its stake in shares of LivaNova by 147.0% during the third quarter. Millennium Management LLC now owns 1,398,340 shares of the company’s stock valued at $110,735,000 after acquiring an additional 832,305 shares in the last quarter. Polar Capital Holdings Plc raised its stake in shares of LivaNova by 1,939.4% during the third quarter. Polar Capital Holdings Plc now owns 728,712 shares of the company’s stock valued at $57,707,000 after acquiring an additional 692,980 shares in the last quarter. Finally, State Street Corp raised its stake in LivaNova by 20.1% in the second quarter. State Street Corp now owns 1,971,476 shares of the company’s stock worth $165,821,000 after buying an additional 329,304 shares in the last quarter. Institutional investors own 94.96% of the company’s stock.
Shares of NASDAQ LIVN traded up $0.21 during midday trading on Thursday, reaching $86.51. 181,261 shares of the company traded hands, compared to its average volume of 396,711. The firm has a market cap of $4.60 billion, a PE ratio of -10.41 and a beta of 0.85. The stock’s 50-day simple moving average is $83.34 and its 200-day simple moving average is $82.82. LivaNova has a 12 month low of $51.59 and a 12 month high of $93.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.79 and a current ratio of 0.98.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.
Read More: Are sell-side analysts objective?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.